BMS-1001

Catalog No.S9610 Batch:S961001

Print

Technical Data

Formula

C35H34N2O7

Molecular Weight 594.65 CAS No. 2113650-03-4
Solubility (25°C)* In vitro DMSO 50 mg/mL (84.08 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
Targets
PD-1/PD-L1 [1]
(Cell-free assay)
253 nM(EC50)
In vitro

BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.[1]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    PD-L1+ aAPC/CHO-K1 cells (aAPCs), PD-1 Effector Cells (ECs)

  • Concentrations

    0.12 μM, 0.3 μM, 1.2 μM, 3 μM

  • Incubation Time

    24 h

  • Method

    For the evaluation of the BMS impact on T cell inhibition by soluble PD-L1, the ECs are stimulated with the anti-CD3 antibody in the presence of the recombinant human sPD-L1. For this, the 96-well white flat bottom plates are coated overnight at 4°C with 5 μg/ml of the anti-CD3 antibody or the isotype control solution in PBS. The antibody solution is removed and the plates are washed 3 times with PBS and dried. sPD-L1 (aa 18–134) is diluted in PBS supplemented with the penicillin/streptomycin solution (100 U/ml final concentration each) in the presence of the BMS-1001 or a corresponding volume of DMSO. Then, 15 μl of the solution is added to each well of the antibodycoated plate. ECs are centrifuged and diluted to 50 000 per ml, and 60 μl of the cell solution is added to each well. The final concentration of sPD-L1 was 10 μg/ml (0.6 μM). The final concentrations of BMS-1001 are: 0.12, 0.3, 1.2 and 3 μM, giving the following BMS:sPD-L1 molar ratios: 1:5, 1:2, 2:1 and 5:1. The cells are cultured for 24 h and the luciferase activity assay is performed using the Bio-Glo Luciferase Assay System.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.